Esperion Therapeutics Inc (ESPR)
Official siteDRUG MANUFACTURERS - SPECIALTY & GENERIC
Last updated: Jul 13, 2026 at 5:00 PM ET
Esperion Therapeutics Inc (ESPR) Financials: Revenue, Profit and Cash Flow
Esperion Therapeutics reported revenue of $403.13M for the fiscal year ended Dec 31, 2025, up 21.3% from the year before. That year, net income was -$22.68M with a net margin of -5.6%, operating cash flow was -$13.09M and free cash flow was -$13.09M. The quarter ended Mar 31, 2026 had revenue of $80.10M and net income of -$25.20M.
Revenue and Margins
The operating margin was 15.0% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $148.36M, a compound annual rate of 18.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $403.13M | +21.3% | 67.9% | 15.0% | -5.6% |
| Dec 2024 | $332.31M | +185.7% | 79.4% | 16.4% | -15.6% |
| Dec 2023 | $116.33M | +54.1% | 62.8% | -133.7% | -179.9% |
| Dec 2022 | $75.47M | -3.8% | 100.0% | -237.8% | -309.6% |
| Dec 2021 | $78.45M | -65.5% | 100.0% | -289.0% | -343.0% |
| Dec 2020 | $227.55M | +53.4% | 100.0% | -53.3% | -63.1% |
| Dec 2019 | $148.36M | N/A | 100.0% | -62.8% | -65.5% |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $403.13M | $332.31M | $116.33M | $75.47M | $78.45M | $227.55M | $148.36M | $0 | $0 | $0 |
| Cost of revenue | $129.22M | $68.60M | $43.27M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $273.91M | $263.71M | $73.07M | $75.47M | $78.45M | $227.55M | $148.36M | $0 | $0 | $0 |
| Research and development | $47.85M | $46.24M | $86.11M | $118.93M | $105.97M | $146.94M | $175.61M | $171.49M | $147.60M | $57.87M |
| Operating income | $60.27M | $54.40M | -$155.56M | -$179.50M | -$226.73M | -$121.40M | -$93.10M | -$204.59M | -$168.98M | -$76.15M |
| Net income | -$22.68M | -$51.74M | -$209.25M | -$233.66M | -$269.11M | -$143.55M | -$97.17M | -$201.81M | -$166.99M | -$74.98M |
| EBITDA | $66.88M | $63.98M | -$148.82M | -$174.45M | -$224.49M | -$119.20M | -$92.98M | -$204.54M | -$168.39M | -$74.88M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.10M | $168.45M | $87.31M | $82.39M | $65.00M | $69.11M | $51.63M | $73.83M | $137.74M | $32.25M | $33.97M | $25.79M |
| Gross profit | $80.10M | $39.22M | $87.31M | $82.39M | $65.00M | $512.00K | $51.63M | $73.83M | $137.74M | -$11.02M | $33.97M | $25.79M |
| Operating income | -$6.58M | $85.23M | -$9.96M | $7.09M | -$22.10M | -$4.42M | -$16.03M | $2.58M | $72.27M | -$42.37M | -$27.53M | -$37.06M |
| Net income | -$25.20M | $61.83M | -$31.33M | -$12.72M | -$40.45M | -$21.32M | -$29.52M | -$61.92M | $61.02M | -$56.34M | -$41.25M | -$49.94M |
Balance Sheet
As of Dec 2025, total debt of $341.28M exceeded cash and equivalents by $173.43M. Shareholder equity was negative, at -$301.96M, as total liabilities of $767.85M exceeded total assets of $465.89M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $465.89M | $343.82M | $205.80M | $247.94M | $381.59M | $353.26M | $214.45M | $143.45M | $277.83M | $245.21M |
| Current assets | $462.57M | $338.00M | $201.06M | $246.68M | $328.97M | $345.90M | $211.71M | $142.63M | $203.92M | $213.58M |
| Cash and equivalents | $167.85M | $144.76M | $82.25M | $124.78M | $208.89M | $304.96M | $166.13M | $36.97M | $34.47M | $38.16M |
| Total liabilities | $767.85M | $732.54M | $660.79M | $571.72M | $578.53M | $449.39M | $194.50M | $64.33M | $33.14M | $16.61M |
| Short-term debt | $91.80M | $54.58M | $0 | $25.53M | $14.08M | $2.59M | $454.00K | N/A | $1.04M | $1.71M |
| Long-term debt | $249.48M | $237.72M | $261.60M | $259.90M | $258.28M | $179.37M | $0 | N/A | $0 | $1.02M |
| Shareholder equity | -$301.96M | -$388.72M | -$454.99M | -$323.78M | -$196.94M | -$96.13M | $19.95M | $79.12M | $244.69M | $228.60M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $462.53M | $465.89M | $364.02M | $347.08M | $324.03M | $343.82M | $314.11M | $352.32M | $373.06M | $205.80M | $221.31M | $234.63M |
| Total liabilities | $770.46M | $767.85M | $815.38M | $780.59M | $750.24M | $732.54M | $684.32M | $696.54M | $667.36M | $660.79M | $631.31M | $606.60M |
| Cash and equivalents | $156.16M | $167.85M | $92.45M | $86.06M | $114.63M | $144.76M | $144.72M | $189.30M | $226.61M | $82.25M | $114.83M | $138.47M |
| Shareholder equity | -$307.93M | -$301.96M | -$451.36M | -$433.51M | -$426.21M | -$388.72M | -$370.21M | -$344.22M | -$294.30M | -$454.99M | -$410.00M | -$371.98M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.09M | -$23.65M | -$135.49M | -$174.83M | -$263.81M | -$85.18M | -$70.34M | -$148.64M | -$131.30M | -$47.73M |
| Capital expenditures | $0 | $317.00K | $0 | $0 | $0 | $869.00K | $953.00K | $151.00K | $19.00K | $94.00K |
| Free cash flow | -$13.09M | -$23.97M | -$135.49M | -$174.83M | -$263.81M | -$86.05M | -$71.29M | -$148.79M | -$131.32M | -$47.82M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $302.73M | N/A | N/A | $0 | $0 |
| Share repurchases | $7.50M | $0 | $0 | $50.00M | N/A | $55.00M | $0 | $0 | N/A | N/A |
| Investing cash flow | $0 | -$317.00K | $42.50M | $8.10M | -$50.48M | $21.36M | $64.23M | $140.45M | -$35.85M | $10.12M |
| Financing cash flow | $36.18M | $86.48M | $50.46M | $32.61M | $268.22M | $201.72M | $136.19M | $10.69M | $163.46M | -$1.56M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.72M | $45.24M | -$4.29M | -$31.42M | -$22.63M | -$34.95M | -$35.33M | -$7.21M | $53.83M | -$37.06M | -$19.32M | -$24.75M |
| Capital expenditures | $189.00K | $189.00K | $0 | $0 | $0 | $0 | $167.00K | $77.00K | $73.00K | $0 | $0 | $0 |
| Free cash flow | -$27.91M | $45.05M | -$4.29M | -$31.42M | -$22.63M | -$34.95M | -$35.49M | -$7.28M | $53.76M | -$37.06M | -$19.32M | -$24.75M |
Frequently Asked Questions About ESPR
What is Esperion Therapeutics' annual revenue?
Esperion Therapeutics reported revenue of $403.13M for the fiscal year ended Dec 31, 2025.
How fast is Esperion Therapeutics' revenue growing?
Revenue was up 21.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 74.8%.
Is Esperion Therapeutics profitable?
No. Esperion Therapeutics reported net income of -$22.68M for the fiscal year ended Dec 31, 2025, with a net margin of -5.6%.
How much free cash flow does ESPR generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.09M minus capital expenditures of $0 produced free cash flow of -$13.09M.
How much debt does Esperion Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $249.48M, short-term debt of $91.80M and cash and equivalents of $167.85M.
ESPR pages: Overview, Financials